Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and Daytrana, a methylphenidate transdermal system. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in the age group of 6 to 17 years o...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Executive Officer and President
Vice President of Operations
Chief Scientific Officer and Vice President
Chief Medical Officer and Executive Vice President of Product Development
Compensation as of Fiscal Year 2013.
Noven Pharmaceuticals, Inc. Key Developments
Noven Pharmaceuticals, Inc. Announces Settlement of Lidoderm(R) Patent Litigation with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc
Apr 16 14
Noven Pharmaceuticals, Inc. announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven's lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven's product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven's product would be a generic version of Endo's Lidoderm(R). The agreement allows Noven to launch its generic Lidoderm(R) product on or after March 1, 2015, if the product is approved by the FDA. The agreement provides for an earlier launch under certain circumstances. Pursuant to the agreement, the litigation on this matter, currently pending in U.S. District Court for the District of Delaware, will be dismissed. Other terms of the settlement were not disclosed. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Actavis plc Enters an Agreement with Noven Pharmaceuticals, Inc. to Settle all Outstanding Patent Litigation
Mar 19 14
Actavis plc announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. Under the terms of the agreement, Noven will grant Actavis a non-exclusive, royalty-bearing license to market its generic Daytrana beginning on September 1, 2015, or earlier under certain circumstances.
Noven Pharmaceuticals Announces Brisdelle(TM) (Paroxetine) Capsules, 7.5 Mg
Nov 5 13
Noven Pharmaceuticals, Inc. announced that Brisdelle(TM) (paroxetine) capsules, 7.5 mg, is now available by prescription nationwide. Brisdelle is the first and only FDA-approved, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes. The availability of Brisdelle offers women with moderate to severe hot flashes an FDA-approved, non-hormonal choice, helping to advance treatment options for menopausal women. Moderate to severe hot flashes -- sudden feelings of intense heat in the body that include sweating -- affect millions of menopausal women in the United States. Previously, hormone therapy was the only FDA-approved treatment for hot flashes associated with menopause and, because many women are unable or unwilling to take hormone therapy, symptoms were often left untreated.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|